Telix Pharmaceuticals has released dosimetry data related to its candidate therapy for prostate cancer. The data provides insights into the distribution and radiation dose delivered to the target tissues during treatment. This information is crucial for understanding the safety and efficacy of the therapy in clinical applications. The findings are expected to contribute to the ongoing development and regulatory evaluation of the treatment.
Related Articles
Don't miss out on breaking stories and in-depth articles.